Earnings Insights

AI-generated analysis of quarterly earnings, concall highlights, and financial performance across Indian listed companies.

How to use these insights

Each article is built from earnings call transcripts and structured rank signals. Start with the latest summary, then open the stock page for the full company view, the concall page for quarter-by-quarter commentary, and the rankings dashboard to compare peers.

Dharmaj Crop Guard Q1 FY25 earnings call: Revenue & Margins | Arthneeti

Q1 FY25

Revenue from Operations for Q1FY25: ₹2,553 million, a 62% year-on-year (YoY) increase from ₹1,575 million in Q1FY24. Key concall takeaways from Dharmaj Crop…

24 Sept 2026

Dharmaj Crop Guard Q3 FY25 earnings call: Revenue & Margins | Arthneeti

Q3 FY25

Q3FY25 Revenue from Operations: ₹1,745 million . Key concall takeaways from Dharmaj Crop Guard Ltd's Q3 FY25 earnings call — and how it ranks against sector…

24 Sept 2026

Dharmaj Crop Guard Q1 FY26 earnings call: Revenue & Margins | Arthneeti

Q1 FY26

Revenue from Operations for Q1 FY26: ₹3,674 Mn, up 44% year-on-year (YoY) from ₹2,553 Mn in Q1 FY25. Key concall takeaways from Dharmaj Crop Guard Ltd's Q1…

24 Sept 2026

Dharmaj Crop Guard Q3 FY26 earnings call: Revenue & Margins | Arthneeti

Q3 FY26

Q3FY26 revenue from operations: ₹1,895 million, a 9% year-on-year (YoY) increase from ₹1,745 million in Q3FY25. Key concall takeaways from Dharmaj Crop Guard…

24 Sept 2026

Dharmaj Crop Guard Q1 FY27 earnings call: Revenue & Margins | Arthneeti

Q1 FY27

Revenue from Operations for Q1 FY27: ₹3,841 Mn, a 5% increase YoY from ₹3,674 Mn in Q1 FY26. Key concall takeaways from Dharmaj Crop Guard Ltd's Q1 FY27…

24 Sept 2026

Anuh Pharma Q2 FY25: Revenue ₹169.35 Cr | Arthneeti

Q2 FY25

Q2 FY25 Revenue: Rs 169.35 Cr (Page 6) . Key concall takeaways from Anuh Pharma Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.

24 Sept 2026

Anuh Pharma Q4 FY25: Revenue ₹198.14 Cr, PAT ₹12.46 Cr | Arthneeti

Q4 FY25

For Q4 FY 2025, operating revenue was ₹198.14 crore, a 2.24% year-on-year increase from ₹193.63 crore in Q4 FY 2024 (derived from annual total revenue…

24 Sept 2026

Anuh Pharma Q1 FY26: Revenue ₹186.48 Cr, PAT ₹8.30 Cr | Arthneeti

Q1 FY26

Operating Revenue for Q1 FY 2026: ₹186.48 Cr, a 35.22% increase year-on-year from ₹137.91 Cr in Q1 FY 2025. Key concall takeaways from Anuh Pharma Ltd's Q1…

24 Sept 2026

Anuh Pharma Q2 FY26 earnings call: Revenue & Margins | Arthneeti

Q2 FY26

185.88 Cr, a -0.32% change quarter-on-quarter; 6 months ended 30/09/2025: Rs. Key concall takeaways from Anuh Pharma Ltd's Q2 FY26 earnings call — and how it…

24 Sept 2026

Anuh Pharma Q3 FY26: Revenue ₹201.18 Cr, PAT ₹13.45 Cr | Arthneeti

Q3 FY26

Q3 FY26 Revenue: ₹201.18 Cr (page 13: Operating Revenue 197.18 + possibly rounding difference clarified on page 6 as ₹201 Cr) . Key concall takeaways from Anuh…

24 Sept 2026

Anuh Pharma Q4 FY26 earnings call: Revenue & Margins | Arthneeti

Q4 FY26

202.12 Cr., a 2.50% increase quarter-on-quarter (Page 14) . Key concall takeaways from Anuh Pharma Ltd's Q4 FY26 earnings call — and how it ranks against…

24 Sept 2026

Anuh Pharma Q1 FY27 earnings call: Revenue & Margins | Arthneeti

Q1 FY27

193.81 Cr, up 3.93% YoY from Rs. Key concall takeaways from Anuh Pharma Ltd's Q1 FY27 earnings call — and how it ranks against sector peers.

24 Sept 2026

Anuh Pharma Q1 FY23 earnings call: Revenue & Margins | Arthneeti

Q1 FY23

116.38 Cr, down 1% YoY from Rs. Key concall takeaways from Anuh Pharma Ltd's Q1 FY23 earnings call — and how it ranks against sector peers.

24 Sept 2026

Anuh Pharma Q3 FY23 earnings call: Revenue & Margins | Arthneeti

Q3 FY23

138.73 Cr, up 21% QoQ (from Rs. Key concall takeaways from Anuh Pharma Ltd's Q3 FY23 earnings call — and how it ranks against sector peers.

24 Sept 2026

Anuh Pharma Q4 FY23 earnings call: Revenue & Margins | Arthneeti

Q4 FY23

157.31 Cr, up from Rs. Key concall takeaways from Anuh Pharma Ltd's Q4 FY23 earnings call — and how it ranks against sector peers.

24 Sept 2026

Anuh Pharma Q1 FY24 earnings call: Revenue & Margins | Arthneeti

Q1 FY24

161.48 Cr., up 39% YoY from Rs. Key concall takeaways from Anuh Pharma Ltd's Q1 FY24 earnings call — and how it ranks against sector peers.

24 Sept 2026

Nelcast Q3 FY24: Revenue ₹323.0 Cr, PAT ₹25.5 Cr | Arthneeti

Q3 FY24

Q3FY24 Total Revenue: ₹323.0 Cr, down 3.2% YoY from ₹333.7 Cr in Q3FY23 (Page 5). Key concall takeaways from Nelcast Ltd's Q3 FY24 earnings call — and how it…

24 Sept 2026

Anuh Pharma Q3 FY24: Capex ₹20 Cr | Arthneeti

Q3 FY24

172.10 Cr, a 15% increase quarter-on-quarter and 31% year-on-year over 9M FY23. Key concall takeaways from Anuh Pharma Ltd's Q3 FY24 earnings call — and how it…

24 Sept 2026

Nelcast Q2 FY25: Revenue ₹335.0 Cr, PAT ₹9.8 Cr | Arthneeti

Q2 FY25

Q2FY25 total revenue: ₹335.0 Cr, down from ₹362.6 Cr in Q2FY24 (approx. Key concall takeaways from Nelcast Ltd's Q2 FY25 earnings call — and how it ranks…

24 Sept 2026

Nelcast Q1 FY27 earnings call: Revenue & Margins | Arthneeti

Q1 FY27

Please provide a different document or specify another query. Key concall takeaways from Nelcast Ltd's Q1 FY27 earnings call — and how it ranks against sector…

24 Sept 2026

Arthneeti Pro · Annual

Every earnings call this season,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access